-
公开(公告)号：EP2265605A1
公开(公告)日：2010-12-29
申请号：EP09722911.6
申请日：2009-03-18
发明人： KOLLA, Naveen, Kumar , MANNE, Nagaraju , GANGULA, Srinivas , NEELAM, Udaykumar , NAREDLA, Anitha , BADDAM, Sudhakar, Reddy , PATIL, Sumeet, Vishwasrao , TUMMALA, Arjunkumar , PEDDIREDDY, Subbareddy , SHINDE, Sachin, Gulabrao , SIGALA, Ashok , MUDUNURU, Satish Varma , TUMMIDI, Madhu, Kiran
IPC分类号： C07D403/12 , C07D235/28 , C07D235/24
CPC分类号： C07D401/12 , A61K9/1635 , A61K9/1652 , A61K47/6951 , B82Y5/00
摘要： Processes for the preparation of dexlansoprazole, an amorphous form of dexlansoprazole, a solid dispersion of amorphous dexlansoprazole and a pharmaceutically acceptable carrier, and processes for their preparation. Also provided are crystalline compounds 2-[(R)-[(4-chloro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and 2-[(R)-[(4-nitro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, and methods for their preparation.
-
公开(公告)号：EP3368159A1
公开(公告)日：2018-09-05
申请号：EP16819162.5
申请日：2016-10-28
IPC分类号： A61P25/06 , A61M5/20 , A61K31/4196 , A61K9/00
CPC分类号： A61K31/4196 , A61K9/0019 , A61K47/02 , A61M5/20
摘要： The present application relates to a method of treating a migraine headache in a patient by administering a pharmaceutical composition including rizatriptan or pharmaceutically acceptable salts thereof contained in a unit dose.
-
公开(公告)号：EP3331524A1
公开(公告)日：2018-06-13
申请号：EP16706279.3
申请日：2016-02-01
发明人： PRABHAKARA, Prabhu , PATIL, Rajesh, Ramesh , GUPTA, Piyush , RAGHUVANSHI, Rajeev, Singh , NAMBOODIRIPAD, Anil, N.
IPC分类号： A61K31/4045 , A61K9/00 , A61K9/08 , A61P25/06
CPC分类号： A61K31/4045 , A61K9/0019 , A61K9/08
摘要： The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.
-
公开(公告)号：EP1848430B1
公开(公告)日：2017-08-02
申请号：EP05855717.4
申请日：2005-12-28
发明人： BARUAH, Anima Maruti Majestic Apartment Bollaram Road , DE, Dibyendu , KHANNA, Ish Kumar , PILLARISETTI, Sivaram , MAITRA, Santanu , ALEXANDER, Christopher W. , SREENU, Jennepalli , DAGER, Indu , SHAVANAS, Alikunju
IPC分类号： A61K31/44 , A61K31/47 , A61K31/495 , A61K31/4965 , C07D213/72 , C07D215/38 , C07D401/02 , C07D471/02 , C07D213/73
CPC分类号： A61K31/506 , A61K31/437 , A61K31/438 , A61K31/47 , A61K31/4709 , A61K31/496 , C07D213/73 , C07D213/74 , C07D215/38 , C07D221/04 , C07D239/78 , C07D241/20 , C07D401/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D498/04
-
公开(公告)号：EP3177610A1
公开(公告)日：2017-06-14
申请号：EP15829684.8
申请日：2015-08-07
IPC分类号： C07D401/14
CPC分类号： C07D401/14 , C07B2200/13 , C07D401/04 , C07D471/16
摘要： A process for preparing Nilotinib hydrochloride Form R5 and Form R6 comprises: step a) providing a solution of Nilotinib free base in acetic acid and optionally an organic solvent, step b) adding hydrochloric acid taken in an organic solvent to the solution of step a), then separating Nilotinib hydrochloride Form R5 (step c), and finally drying at about 100° C. to 150° C. to obtain Nilotinib hydrochloride Form R6.
摘要翻译： 制备R5型和R6型盐酸尼洛替尼的方法包括：步骤a）提供尼罗替尼游离碱在乙酸和任选的有机溶剂中的溶液，步骤b）将盐酸置于有机溶剂中加入到步骤a） 然后分离盐酸尼洛替尼形式R5（步骤c），最后在约100℃至150℃下干燥以获得盐酸尼洛替尼形式R6。
-
公开(公告)号：EP3058362A4
公开(公告)日：2017-03-22
申请号：EP14854678
申请日：2014-10-15
CPC分类号： G01N33/6854 , C07K16/065 , G01N33/68 , G01N2800/52
摘要： The present invention discloses an in-vitro method for determining the fate of protein variants upon administration to a subject. Also provided is a means for establishing comparability between two or more distinct therapeutically effective preparations of the same therapeutic protein.
-
7.发明授权
公开(公告)号：EP2831054B1
公开(公告)日：2016-11-30
申请号：EP13767847.0
申请日：2013-03-27
发明人： DAHANUKAR, Vilas Hareshwar , KUNHIMON, Syam Kumar Unniaran , TIMMANA, Upadhya , PAL, Abir Kumar , MACHA, Mahendar , MEESALA, Venkata Madhubabu , THALABATHULA, Krishna Mohan , RAMANATHAN, Shankar
IPC分类号： C07D311/76 , C07C57/38 , C07C39/15
CPC分类号： C07D311/04 , C07C51/09 , C07C59/52 , C07C211/27 , C07D311/16 , C07D311/20 , C07C59/48
-
公开(公告)号：EP2743255B1
公开(公告)日：2016-06-22
申请号：EP13197519.5
申请日：2013-12-16
发明人： Kumar, Vujjini Satish , Rao, Badarla Venkata Krishna , Charyulu, Kandala Sreenadha , Praveen, Cherukupally , Reddy, Yerraguntla Sesha , Dey, Archan
IPC分类号： C07C233/18 , A61P25/24 , A61K31/165
CPC分类号： C07C233/18 , C07B2200/13
-
公开(公告)号：EP2812314A1
公开(公告)日：2014-12-17
申请号：EP13745996.2
申请日：2013-02-06
发明人： JACKSON, Mark P
IPC分类号： C07C405/00 , C07C59/68
CPC分类号： C07C67/475 , C07C69/732 , C07C69/736 , C07C211/03 , C07C211/04 , C07C211/05 , C07C211/06 , C07C211/07 , C07C211/09 , C07C211/11 , C07C211/27 , C07C211/35 , C07C405/00 , C07C2601/08 , C07C2601/14 , C07D295/027 , C07D311/94
摘要： The present application relates to amine salts of prostaglandin analogs and their uses for the preparation of substantially pure prostaglandin analogs. Specific embodiments relate to amine salts of tafluprost and their uses for the preparation of substantially pure tafluprost.
-
10.发明授权PRODUCTION OF TRANS-4-AMINOCYCLOPENT-2-ENE-1-CARBOXYLIC ACID DERIVATIVES 有权生产反式-4-氨基环戊烷-2- EN-1CARBOXYLSÄUREDERIVATEN
公开(公告)号：EP2448916B1
公开(公告)日：2014-09-03
申请号：EP10794811.9
申请日：2010-07-02
IPC分类号： C07C231/16 , C07C233/52 , C07C231/20 , C07C231/24 , C07C269/06
CPC分类号： C07C231/20 , C07B2200/09 , C07C231/24 , C07C233/52 , C07C269/06 , C07C2601/10 , C07C271/24
-
-
-
-
-
-
-
-
-
搜索结果
248 条记录 (耗时 0.025 秒)
